Brazil · Delayed Price · Currency is BRL Blau Farmacêutica Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 17% year-over-year with margin expansion and zero leverage, driven by strong public and private channel performance and robust product launches. New production lines and pipeline approvals are expected to accelerate growth, with EBITDA margin set to improve further.
Fiscal Year 2025
-
2025 saw strategic divestment, record investments in biotech, and improved margins despite a 3% revenue drop. Net income rose 39%, and new launches plus expanded capacity set the stage for stronger, less volatile growth in 2026.
-
Revenue and gross margin remained strong, with net income up 52% year-over-year. Capacity constraints limited growth, but major expansions and new product launches are set to drive a 70% increase in production and 60% growth in launches over the next three years.
-
Revenue remained stable year-over-year amid capacity constraints, but gross margin and EBITDA reached post-pandemic highs. New production lines, a strong pipeline, and the Prothya exit position the company for accelerated growth and strategic investments.
-
Revenue grew 4% year-over-year in Q1 2025, with strong 15% growth in the private hospital segment and a 50% increase in net income. Investments in biotechnology and new product launches support a robust outlook, despite temporary impacts from regulatory and supply chain transitions.
Fiscal Year 2024
-
Achieved record quarterly revenue of BRL 474 million, up 31% year-over-year, with strong growth in the hospital segment and improved margins. R&D investment remained high, and integration of Bergamo advanced, while focus shifted to private market sales and Latin American expansion.
-
Q2 2024 saw record revenue and margin expansion, driven by strong private market growth, new product launches, and operational efficiencies. Strategic investments in R&D, capacity, and partnerships position the company for continued growth, with robust cash and low leverage.